Servier Egypt, a leading player in the pharmaceutical industry and part of the global Servier Group, proudly marked its ...

On World Cancer Day, Servier reaffirms its commitment to the fight against cancer by focusing on oncology as a central part of its Research & ...

Servier India Pvt. Ltd. has launched a single-pill combination (SPC) of Bisoprolol/Perindopril in India under the brand name Cosyrel, which is approved as a substitution therapy for the treatment of ...

Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...

Servier is extending its pact with Google Cloud as the French biopharma points to 60 examples of how generative artificial intelligence could improve its drug development processes. The two ...

Independent French drugmaker Servier, which is governed by a foundation, has published its 2023/24 financial year results and reflected on the major milestones of the year. For the 2023/2024 financial ...

French pharmaceutical company Servier and Google Cloud have announced an expanded five-year partnership aimed at leveraging artificial intelligence (AI) and generative AI to accelerate drug research ...

S-95024 is under clinical development by Les Laboratoires Servier and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition ...

S-95035 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success ...

H. Lundbeck A/S (Lundbeck) announces that, after 12 years of dedicated service on Lundbeck’s Board of Directors, Lars Søren Rasmussen has informed his decision not to seek re-election at the Annual ...